ME Therapeutics Holdings Inc. (CSE:METX)

Canada flag Canada · Delayed Price · Currency is CAD
4.100
-2.900 (-41.43%)
Oct 8, 2025, 3:59 PM EDT
-41.43%
Market Cap121.32M
Revenue (ttm)n/a
Net Income (ttm)-1.17M
Shares Out29.59M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,311
Average Volume687
Open5.000
Previous Close7.000
Day's Range4.000 - 5.000
52-Week Range2.100 - 11.000
Beta-0.28
RSI46.11
Earnings DateNov 27, 2025

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol METX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.